valu usd unless otherwis note
gx advair shift focu base busi
weak guidanc risk view
view fda identifi minor defici gener advair
relay debat expect
two issu have/do think base busi pressur wors
let pipelin increasingli need backfil ii
street meaning over-model gx advair stock like pull back
tomorrow/through guidanc risk real better entri point
announc expect gener advair
add debat outlook littl known around minor
defici fda identifi expect provid
comprehens updat follow receipt
revisit estim reflect recent updat includ approv
fulphila push gener advair approv
risk-adjust lower full-year ep advair
one larger profit opportun like increasingli need
add near-term risk guidanc see primer
recent thought set-up clear think guidanc risk
specif two issu think base busi
weaker let reli channel check
greater relianc pipelin convers ii street least
overestim gener advair contribut
two factor reason anticip near-term pull-back
despit materi impact gener advair year need
pipelin add expect investor focu pick
ep target need remain level link execut incent
compens said sever time discuss
manag focus oper profit target
influenc shorter term capit alloc decis ie
billion late share repurchas clear think one
best gener pipelin understand frustrat
mani sharehold point close ev/ebitda discount
teva grow valuat discount need
question investor
current attend igba confer budapest see
confer preview week ahead meet
sever industri contact updat come shortli
 big discuss point alreadi industri
particip beyond ou continu
increasingli import region global gener manufactur
compani move diversifi geograph sale mix off-set us
gener pressur despit us gx advair particularli lever
total revenu come ou growth
continu outpac us
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
view solid long-term pipelin
diversifi revenu base howev think
immun broader sector challeng pressur
gener sector pressur worsen like
peer lever capit structur limit financi
flexibl continu risk particularli us gener
follow primari driver thesi stock
face mani sector headwind
pressur peer given diversif pipelin
strength view compani favor posit
rel smaller peer
see fewer catalyst near term reduc financi
flexibl least short term
long-term growth outlook still appear stabl
increasingli diversifi global footprint import
addit potenti competit epipen gener
copaxon see lower growth peer
risk view bigger swing factor stock revolv
around success integr meda potenti
price pressur across core gener portfolio ramp
fda approv outlook inabl gain approv key
pipelin opportun advair
upcom potenti catalyst event focu
potenti guidanc updat addit
gener copaxon approv competitor
addit accret use capit debt paydown
bloomberg capit market estim upside/downside/target
base case scenario see stock price impli
price-to-earnings ep ev/ebitda
steadi new gener approv activ low teen us
gener eros base busi
addit accret though assum
addit debt pay buyback outer year
upsid scenario see valu impli price-to-earnings
ep
inflect higher gener approv activ continu
accret supplement organ growth
portfolio addit debt paydown buyback outer
limit competit high-valu gener greater-
downsid scenario see valu impli p/
 ep
greater price pressur across us gener portfolio
lead gross margin depress
slowdown ou fail off-set pressur us
failur maintain steadi pipelin convers off-set
exhibit
 incom guid flat growth north guid hsd growth eurest guid hsd growth rowoth gener total revenu guid gross profit guid guid total revenuessg guid total revenuesoper incom incom incom tax incom guid incom prefer dividend adjust net guid billionep adjust guid dilut share guid million guid billion growth ebitda analysi net margin guid guid total guid total revenuesoper expens guid net incom pharmaceuticals/specialti
price target base equal price-to-earnings ev/ebitda use target
multipl gener line specialti peer believ
reflect current sector challeng heighten leverag rel histor level
impli return price target support sector perform rate
risk rate price target
risk rate price target includ limit earlier-than-expect
approv key product advair extend delay accret drive
favor accret addit pipelin surpris
lead global gener manufactur base pittsburgh pennsylvania employ
peopl global compani found transform
last sever year notabl acquisit merck kgaa
compani benefit differ revenu sourc help grow
eu auster headwind us comp strength recent year
